Quick Answer
Immunome Inc. reported Stockholders Equity of $634.34 million for fiscal year 2025.
Immunome Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $634.34M | +250.1% |
| 2024 | $181.16M | +51.1% |
| 2023 | $119.88M | +619.9% |
| 2022 | $16.65M | -65.4% |
| 2021 | $48.19M | +16.5% |
| 2020 | $41.34M | +216.0% |
| 2019 | -$35.63M | -41.4% |
| 2018 | -$25.20M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $263.92M | +22.8% | -2.0% |
| June 30, 2025 | $269.27M | +6.1% | -12.3% |
| March 31, 2025 | $307.13M | +7.5% | +69.5% |
| December 31, 2024 | $181.16M | +51.1% | -15.7% |
| September 30, 2024 | $214.91M | +3437.0% | -15.3% |
| June 30, 2024 | $253.84M | +2618.3% | -11.1% |
| March 31, 2024 | $285.57M | +1960.1% | +138.2% |
| December 31, 2023 | $119.88M | +619.9% | +1873.0% |
- Immunome Inc. showed an increase of +250.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2025 period, Immunome Inc.’s stockholders equity has grown by 2616.7% (from -$25.20 million to $634.34 million).
- The most recent figure is from Immunome Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: